deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 8-arm NCT03398135

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (COMMAND)

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis

Sponsor: AbbVie

Conditions Ulcerative Colitis (UC)
Interventions placebo for risankizumab risankizumab
Updated 42 times since 2018 Last updated: Jan 16, 2026 Started: Aug 28, 2018 Primary completion: Sep 30, 2028 Completion: Feb 28, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03398135, this PHASE3 trial focuses on Ulcerative Colitis (UC) and remains ongoing. Sponsored by AbbVie, it has been updated 42 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

42 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 37 earlier versions

  1. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  8. Jun 2022 — Feb 2023 [monthly]

    Enrolling By Invitation PHASE3

  9. Sep 2021 — Jun 2022 [monthly]

    Enrolling By Invitation PHASE3

  10. Jun 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE3

  11. Apr 2021 — Jun 2021 [monthly]

    Enrolling By Invitation PHASE3

  12. Jan 2021 — Apr 2021 [monthly]

    Enrolling By Invitation PHASE3

  13. Nov 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE3

    Status: Recruiting → Enrolling By Invitation

  14. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  15. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  16. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  17. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  18. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  19. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  20. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  21. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  22. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  23. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  24. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  25. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  26. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  27. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  28. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  29. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  30. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  31. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  32. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  33. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  34. Aug 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE3

  35. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE3

  36. May 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE3

  37. Feb 2018 — May 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abiko-shi, Japan , Alexandria, Egypt , Alingsås, Sweden , Almada, Portugal , Amiens, France , Amsterdam, Netherlands , Anderlecht, Belgium , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Anzorey, Russia and 335 more locations